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Abstract
Background: Development of tailored treatment based on immunohistochemical profiles (IPs) of tumors for cancers of
unknown primary is needed.
Methodology/Principal Findings: We developed an algorithm based on primary known adenocarcinoma for testing
sensitivity and specificity. Formalin-fixed paraffin-embedded tissue samples from 71 patients of unfavorable subsets of
unknown primary adenocarcinoma were obtained. We examined 15 molecular markers using the algorithm incorporating
these IPs and classified the tumours into 9 subsets based on the primary tumour site. The sensitivity and specificity of this
algorithm were 80.3% and 97.6%, respectively. Apparent primary sites were lung in 17 patients, digestive organs in 13,
gynecological organs in 9, prostate in 7, liver or kidney in 6, breast in 4, urothelial organ in 2, biliary tract and pancreatic
profile in none, and unclassified in 13. The response rate to chemotherapy was highest for the gynecological IPs. Patients
with gynecological or lung cancer IPs had longer median progression-free survival than those with others: 11.2 months for
gynecological IPs (p,0.001) and 6.8 months for lung IPs (p=0.05). Lung, digestive, prostate, and gynecological profiles were
associated with significantly longer median survival time than the other profiles. Multivariate analysis confirmed that the IPs
were independent prognostic factors for survival.
Conclusions/Significance: The IPs identified in this study can be used to further stratify patient prognosis for unfavorable
subsets of unknown primary adenocarcinoma.
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Introduction
Cancers of unknown primary site (CUPs) account for
approximately 3% of all malignant neoplasms [1]. CUPs are
defined as a heterogeneous group with metastatic disease for which
the site of origin cannot be identified at the time of diagnosis
despite careful clinical and laboratory examination [2]. Adeno-
carcinoma accounts for about 50% of CUPs, and unfavorable
subtypes of heterogeneous adenocarcinomas are generally treated
with platinum doublet chemotherapy regimens, with 6–12 months
median overall survival [3,4,5,6].
Chemotherapy regimens vary by institute for unfavorable
subtypes of CUPs; however, the prognosis remains poor. Because
CUPs comprise heterogeneous neoplasms, investigators have
focused on developing tailored treatments using modern ap-
proaches, identifying molecular targets for CUP-specific therapy,
identifying the primary cancer site and applying disease-oriented
therapy, or identifying the primary site by gene profiling assay
using complementary deoxyribonucleic acid (cDNA) or oligonu-
cleotide microarrays [7,8]. An alternative approach is staining
samples using immunohistochemistry (IHC) to determine the
primary tumor site. Recent studies have demonstrated that IHC
can identify unique subsets of CUPs, and that organ-specific
chemotherapy for these subsets may have benefit [9]. However,
classification of CUPs by IHC using conventional antibodies
requires further development to improve sensitivity and specificity
in determining the primary site [10].
Through recent advancements in IHC, additional organ-
specific antibodies have become available [9,11,12,13,14,15,16,
17,18,19,20,21,22,23,24], including the estrogen receptor (ER),
progesterone receptor (PgR), mammaglobin, gross cystic disease
fluid protein-15 (GCDFP-15), CDX2, thyroid transcription factor-
1 (TTF-1), Wilms tumor susceptibility gene 1 (WT-1), paired box
gene 8 (PAX8), prostate-specific antigen (PSA), and uroplakin
with conventional antibodies including cytokeratin (CK) 7 and
CK20. Use of these biomarkers has the potential to identify the
primary tumor site with greater sensitivity and specificity [25,26].
Furthermore, K-ras gene mutation analysis may assist in
determining the primary site when combined with IHC for
pancreatic or bile duct cancer [27,28]. Improving treatment of
CUPs requires identification of the primary tumor site using
molecular markers and application of primary tumor site-specific
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for study and conducted the present single-center retrospective
biomarker analysis to provide the basis for an upcoming
prospective clinical trial.
Results
Patient characteristics and immunohistochemistry profile
Patient characteristics are listed in Table 1. Nearly 50% of
biopsy samples were taken from lymph nodes. Other biopsy sites
included lacrimal grand, chest wall, vaginal, and brain. A
carboplatin and paclitaxel regimen was used most frequently
(40%), followed by a carboplatin and irinotecan regimen (31%).
The carboplatin and irinotecan, carboplatin and S1, and cisplatin
and docetaxel regimens were prospectively evaluated in our phase
II trials [5,6] or ongoing prospective trial.
We examined the sensitivity and specificity of the algorithm
(Figure 1) by using known primary tumors which were surgically
resected; 10 lung adenocarcinoma; 11 ovarian adenocarcinoma;
10 endometrial adenocarcinoma; 10 breast adenocarcinoma; 10
prostate adenocarcinoma; 10 urothelial adenocarcinoma; 10
colorectal adenocarcinoma; 10 gastric adenocarcinoma; 11
pancreatic adenocarcinoma; 5 biliary tract adenocarcinoma; 10
hepatocellular adenocarcinoma; and 10 renal cell adenocarcino-
ma. Overall sensitivity and specificity of this algorithm to identify
the primary site were 80.3% and 97.6%, respectively. For each
subset, the sensitivity and the specificity were as follows; lung
profile, 100% and 100%; gynecology profile, 100% and 95.9%;
breast profile, 90% and 100%; prostate profile, 100% and 94.5%;
urothelial profile, 20% and 99%; digestive profile, 85.7% and
96.9%; biliary tract or pancreas profile, 0 and 94.7%; and liver or
kidney profile, 80% and 100%, respectively.
The primary tumor sites based on the immunohistochemical
profiles (IPs) for the 71 unknown primary patients were the lung
for 17 patients, digestive organs for 13, gynecological organs for 9,
prostate for 7, liver/kidney for 6, breast for 4, urothelial for 2, and
were not unclassified for 13 patients (Table 2).Figures 2 and 3
show typical IHC results for the breast and lung profiles.
The CK7-positive and CK20-negative cohort was the most
frequent (Figure 1). We found that 7 tumors did not exhibit
profiles in accordance with the algorithm: four were CDX2-
positive but CK20-negative and were classified into the digestive
profile, one was negative for both mammaglobin and GCDFP-15
and all other markers other than CK19 and ER (Allred score was
7) [29] and was classified into the breast profile, and two were
positive for uroplakin and both negative for CK7 and CK20 and
were classified into the urothelial profile. CK17 was also positive in
9 patients according to the algorithm that did not have K-ras gene
mutations. For remaining 13 patients, a specific primary profile
was not identified. Among the 17 lung profile patients, 15 samples
were available for EGFR mutation analysis and one demonstrated
mutation of codon 858 in exon 21. For digestive IP, 9 samples
were available for K-ras mutation analysis and 3 of these were
positive (codon12 TGT, codon12GTT, and codon12 GAT).
Response evaluation and survival analysis
The overall response rate was 31%. Response rates by profile
are listed in Table 2. A higher response rate was observed for the
gynecological profile (67%) than for the other profiles. Progres-
sion-free survival varied significantly by IP. The median PFS was
6.8, 11.2, and 11.0 months for the lung, gynecological, and
prostate IPs, respectively, while those of the other IPs, including
the digestive, liver/kidney, breast, urothelial, prostate, and
unclassified profiles were 4.8, 3.0, 4.5, 2.7, and 4.9 months,
respectively (Figure 4). Univariate and multivariate analyses of
PFS are shown in Table 3. In the multivariate analysis, PFS was
significantly longer for the gynecological and lung profiles than for
the other profiles. Likewise, the median survival time was 23.3,
17.4, 18.0, and 13.8 for the gynecological, lung, prostate, and
digestive IPs, respectively, while others including the liver/kidney,
breast, urothelial, and unclassified IPs were 6.6, 8.2, 5.0, and 10.0
months, respectively (Figure 5). In the multivariate analysis, bone
metastasis, poor performance status, and male patients, in addition
to the IP, were independent prognostic factors. Lung, gynecolog-
ical, digestive, and prostate profiles had significantly longer
survival times than the other profiles (Table 4).
Discussion
In this study, we developed a panel for identifying the primary
cancer origin of CUPs using our stocked tissue samples and
through immunohistochemical profiling along with gene mutation
analysis. The sensitivity and specificity of the panel validated by
primary known adenocarcinomas were 80.3% and 97.3%. Using
this panel, 81.7% of the patients were classified as having a specific
primary tumor profile. We then analyzed clinical outcomes
according to the panel. The response rate was higher for patients
Table 1. Patient characteristics at diagnosis.
Variable n (%)
Age Median (range) 62 (36–78)
$65 yr 25 (35)
,65 yr 46 (65)
Gender Male 40 (56)
Female 31 (44)
Performance status 0 3 (4)
1 39 (55)
2 29 (41)
Sites of biopsy Lymphnodes 38 (54)
Bone or Bone marrow 10 (14)
Liver 6 (9)
Gastrointestinal tract 4 (6)
Skin 2 (3)
Adrenal gland 2 (3)
Others 8 (10)
Bone metastasis Yes 13 (18)
No 58 (82)
Liver metastasis Yes 6 (9)
No 65 (91)
Lung metastasis Yes 12 (17)
No 59 (83)
Lymph node metastasis No 18 (25)
Yes 53 (75)
Treatment regimen Cisplatin or carboplatin/
docetaxel
16 (22)
Carboplatin/irinotecan 22 (31)
Carboplatin/paclitaxel 29 (41)
Carboplatin/S1 or FOLFOX 4 (6)
FOLFOX: 5FU, oxaliplatin, and l-leukovorin.
doi:10.1371/journal.pone.0031181.t001
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was also significantly longer for patients with the gynecological and
lung profiles than for those with the liver/kidney profile. The
multivariate analysis revealed that patients with the gynecological,
lung, prostate, and digestive profiles had significantly longer
survival than the other patients. Clinical course of survival seems
to be consistent with diagnosis of their primary cancers.
In this analysis, we used organ-specific antibodies, including
TTF-1 for lung cancer, WT-1 or PAX8 for gynecological cancers,
mammaglobin or GCDFP-15 for breast cancer, PSA for prostate
cancer, CDX2 for gastrointestinal cancers, and uroplakin for
urothelial cancers. In validation of the panel by using these
markers, lung, gynecology, breast, prostate, digestive, and liver/
kidney profile had high sensitivity and specificity. Notably, liver/
kidney profile which organ specific markers are currently
unavailable achieved high sensitivity and specificity by deleting
other possibilities with CK7 and CK20 negativity. However,
urothelial and biliary tract or pancreatic profile had lower
Figure 1. Identification of the primary tumor site by immunohistochemistry and gene analysis. Thirteen patients were not sorted to
specific profiles and an additional 8 patients were not classified into the profiles in the manner defined by the algorithm. Two patients presenting
with both CK72 and CK20-positive were classified into an unclassified profile. Ten patients with CK7-positive and CK20-negative were classified into
an unclassified profile. Three patients with CK7-positive and CK20-negative were classified into the digestive (n=1) and urothelial (n=2) profiles. One
patient with both CK72 and CK20-negative was classified into the unclassified profile. Four patients with both CK72 and CK20-negative were
classified into the digestive (n=3) and lung (n=1) profiles. Footnote: * Estrogen receptor- or progesterone receptor-positive with CK19-positive.
doi:10.1371/journal.pone.0031181.g001
Table 2. Primary tumor site of unfavorable subsets of adenocarcinoma of unknown primary determined by a
immunohistochemistry profile of 15 markers and the relationship to response rate to platinum doublet regimens.
Profile n (%) Complete response Partial response Response rate (%)
Lung 17 (24) 2 3 17.6
Digestive 13 (18) 0 2 15.4
Gynecological 9 (13) 3 3 66.7
Prostate 7 (10) 0 2 28.6
Liver/Kidney 6 (8) 0 2 33.3
Breast 4 (6) 0 1 25.0
Urothelial 2 (3) 0 0 0
Not identified 13 (18) 2 2 30.8
doi:10.1371/journal.pone.0031181.t002
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approaches may have some value [7,8].
These antibodies used in this analysis are valuable for the cohort
with adenocarcinoma, because the majority of other cancers that
arise from the head and neck, esophagus, and uterine cervix can
be excluded. We did not divide the liver/kidney profile into liver
and kidney groups, as the first-line treatment for these metastatic
diseases is similar [30,31]. Further, we consider gynecologic profile
may not be necessary to be classified into ovary, endometrial, and
cervical adenocarcinoma in the situation of adenocarcinoma of
unknown primary because chemotherapies for these cancer
become similar in advanced disease [32,33,34]. The possibilities
Figure 3. An adenocarcinoma showing typical presentation of the lung profile by immunohistochemistry. Hematoxylin-eosin stain (left
upper), cytokeratin (CK)7 (right upper), CK20 (left lower), and thyroid transcription factor-1 (TTF-1) (right lower). CK7 and TTF-1 are positive in the
cytoplasm and nuclei of tumor cells, respectively (original magnification 6200).
doi:10.1371/journal.pone.0031181.g003
Figure 2. An adenocarcinoma showing typical presentation of the breast profile by immunohistochemistry. Hematoxylin-eosin stain
(left upper), cytokeratin (CK)7 (right upper), CK20 (left lower), and mammaglobin (right lower). CK7 and mammaglobin are positive in the cytoplasm
of tumor cells (original magnification 6200).
doi:10.1371/journal.pone.0031181.g002
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immunohistochemistry profiles.
doi:10.1371/journal.pone.0031181.g004
Table 3. Prognostic significance for progression-free survival of the immunohistochemistry profile and other parameters by Cox
univariate and multivariate analyses.
Univariate Multivariate
HR 95%CI p HR 95%CI p
No. of 1–2 organs
metastases $3 organs 1.12 0.66–1.90 0.67 0.92 0.43–1.99 0.84
Liver No
metastasis Yes 1.30 0.55–3.04 0.55 1.36 0.51–3.62 0.54
Bone No
metastasis Yes 1.80 0.94–3.45 0.08 1.73 0.77–3.89 0.19
Performance 0–1
score 2 2.86 1.71–4.77 ,0.001 3.32 1.81–6.08 ,0.001
Gender Female
Male 0.70 0.43–1.14 0.15 0.33 0.17–0.66 0.002
Age $65
,65 0.62 0.37–1.10 0.08 0.57 0.32–1.03 0.06
Profile Liver/Kidney
Prostate 0.30 0.10–0.93 0.04 0.38 0.09–1.52 0.17
Digestive 0.52 0.19–1.42 0.20 0.44 0.13–1.46 0.18
Breast 0.78 0.22–2.77 0.70 0.48 0.13–1.82 0.28
Urothelial 1.58 0.31–7.98 0.58 0.46 0.08–2.58 0.38
Lung 0.27 0.10–0.72 0.009 0.31 0.10–1.00 0.05
Gynecological 0.18 0.06–0.59 0.004 0.08 0.02–0.30 ,0.001
Not identified 0.44 0.16–1.20 0.11 0.40 0.14–1.21 0.11
HR, hazard ratio; CI, confidence interval; PS, performance status.
doi:10.1371/journal.pone.0031181.t003
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multivariate analyses.
Univariate Multivariate
HR 95%CI p HR 95%CI p
No. of metastasis 1–2
$3 1.42 0.82–2.45 0.21 1.01 0.44–2.29 0.99
Liver metastasis No
Yes 1.25 0.53–2.96 0.61 1.11 0.37–3.30 0.86
Bone metastasis No
Yes 2.08 1.03–4.19 0.04 3.52 1.44–8.64 0.01
PS 0–1
2 1.89 1.11–3.21 0.02 1.99 1.05–3.78 0.04
Gender Female
Male 0.64 0.38–1.09 0.10 0.46 0.23–0.95 0.04
Age $65
,65 0.54 0.3–0.97 0.04 0.56 0.28–1.12 0.1
Profile Liver/Kidney
Prostate 0.14 0.04–0.48 0.002 0.09 0.02–0.45 0.003
Digestive 0.27 0.09–0.81 0.02 0.23 0.06–0.81 0.02
Breast 0.41 0.11–1.50 0.18 0.31 0.07–1.28 0.11
Urothelial 2.24 0.42–11.9 0.34 1.50 0.23–9.58 0.67
Lung 0.18 0.06–0.50 0.001 0.20 0.05–0.72 0.01
Gynecological 0.13 0.04–0.46 0.001 0.09 0.02–20.35 0.001
Not identified 0.36 0.13–1.01 0.05 0.37 0.12–1.09 0.07
HR, hazard ratio; CI, confidence interval; PS, performance status.
doi:10.1371/journal.pone.0031181.t004
Figure 5. Overall survival curve by the Kaplan-Meier method for the groups with each primary site as classified by the
immunohistochemistry profiles.
doi:10.1371/journal.pone.0031181.g005
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digestive cancer when limited to adenocarcinoma of unknown
primary [35,36,37,38].
The algorithm we generated for orienting primary has
value
Immunohistochemistory is generally done in routine work for
the diagnosis of adenocarcinoma of unknown primary in many
cancer centers. Therefore, there is no additional skill or tool in the
procedure of diagnosis [10,25]. Previously, Dannis et al. developed
algorithm to identify the useful antibodies, specific for primary
sites [25]. They developed diagnostic panel to examine 7 primary
site (breast, colon, lung, ovary, pancreas, prostate, and stomach) by
using FFPE samples of primary known cancers, but liver and
kidney origin cancer were not included. The accuracy of diagnosis
is 88%, however, the problem is that the algorithm is not applied
for unknown primary cancer and the clinical outcomes divided by
the algorithm is unknown. Therefore, the beneficiary to apply the
algorithm for identification of unknown primary cancer is unclear.
Centeno et al. also did the similar approach to Dannis by using
origin known cancers [39]. They also excluded hepatocellular
carcinoma and renal cell carcinoma. The outcome of the
algorithm is not validated to unknown primary cancer in relation
to clinical outcomes. We developed our panel referencing to their
result in part and specified to adenocarcinoma of unknown
primary including hepatocellular carcinoma and renal cell
carcinoma, and the results of the algorithm for unknown primary
adenocarcinoma were consistent with the clinical outcomes of
primary known cancers.
Horlings et al. reported identification of primary site of unknown
primary adenocarcinoma by oligonucleotide microarray [8]. The
accuracy was 83%, however, lung, clear cell ovary, pancreas, and
stomach origin were misidentified up to 100%. Interestingly, they
used immunohistochemical result of unknown primary to orient
primary as a reference. However, the immunohistochemical
reference arm they used was poor as only a few markers were
stained. They also presented a single case study according to gene
expression profile but the clinical outcomes for others are unclear.
Varadhachary et al. used 10 gene markers by real time PCR to
identify the primary site in cancer of unknown primary [40]. They
did not show the validated result of the panel in known primary
cancer. RNA was lost in 13% before testing and the yield of
orientation was somewhat low (approximately 70%). They also
used immunohistochemistry as a reference including CDX2 for
colon cancer, TTF-1 for lung cancer. For ovarian cancer identified
by their panel, survival seems not consistent with clinical features
of ovarian cancer.
This study has some limitations. First, the prognostic value of
each IP was potentially underpowered, as the number of patients
in each subgroup was somewhat small, not allowing the response
rate, PFS, and OS to be compared to historical control data.
Second, the results need to be validated in a prospective manner
by applying standard treatments for identified primary profiles, to
go beyond simply identifying prognostic factors for unknown
primary adenocarcinoma. Further biomarker investigation may be
valuable for subgroups other than the EGFR mutation for the lung
profile, the K-ras mutation for the digestive profile, and human
epidermal growth factor receptor-2 overexpression for breast
profile.
In this study, we revealed the prognostic value of a panel
composed of immunohistochemistry profiles for patients with
adenocarcinoma of unknown primary who received platinum
doublet chemotherapy. Orienting primary sites either IHC or
cDNA microarray in patients with CUPs is not good enough, we
need to examine survival benefit when applying organ-oriented
standard chemotherapies for patients with CUPs. Our results may
encourage a prospective randomized trial to compare standard
platinum doublet chemotherapy with treatment determined by the
IP. This approach may assist in developing new treatment strategy
compared to a single arm platinum combination trial.
Methods
Patients
Patients diagnosed with CUPs between 1997 and 2008 at the
National Cancer Center Hospital were selected from our database.
The following procedures were performed and criteria applied for
diagnosing CUPs: careful physical examination by physicians,
urologists, dermatologists, otolaryngologists, and gynecologists
(female patients); computer tomography, mammography (female
patients), gastrointestinal endoscopy, colonoscopy or stool occult
blood testing if colonoscopy was not feasible; urinary cytology with
negative results; biochemical and blood tests; no elevated levels of
organ-specific serum tumor markers, including cancer antigen 125
(CA 125) or PSA; and histologically confirmed metastatic cancer.
All the patients undertook biopsy (core needle biopsy or open
biopsy) before first-line chemotherapy for diagnosis.
The eligibility criteria for this study were as follows: patients
who received platinum doublet chemotherapy as first-line
chemotherapy; patients diagnosed with adenocarcinoma; perfor-
mance status (PS) 0–2; age $18; and patients who provided
informed consent for their tissue samples to be used for the
analysis. Exclusion criteria for this study were as follows: patients
with favorable subsets [1], i.e., females with axillary lymph node
metastasis; females with elevation of serum CA 125 levels with
peritoneal metastasis; and males with elevation of serum PSA
levels, elevation of serum alpha fetoprotein, human chronic
gonadotropin, or suspected of extragonadal germ cell tumors.
Male patients with intensive physical examinations, including
biopsy for prostate cancer, without significant elevation of serum
PSA levels and without evidence of osteogenic changes in bone
were included in this analysis. Females without significant
elevations of serum CA125 and with no evidence of disease in
genital organs or the peritoneum were also included in this
analysis. This study was approved by the institutional review board
of the National Cancer Center and conducted in accordance with
Japanese ethics guidelines for clinical and epidemiological studies,
which took effect in August 2007. Informed consent for all the
participants were done by the patients or their family before
starting this research by sending mail to allow tissue samples use
for clinical research.
Immunohistochemistry and polymerase chain reaction
We used formalin-fixed paraffin-embedded tissue samples for
IHC and gene analysis. For IHC, paraffin sections were treated
with hydrogen peroxide to inactivate endogenous peroxidases after
deparaffinization in xylene and rehydration in ethanol. Slides were
placed in 10 mmol/l of citrate buffer at pH 6.0 (REAL
TM Target
Retrieval Solution; Dako, Tokyo, Japan), then autoclaved for
antigen retrieval. Primary antibodies were incubated for 1 h and a
secondary antibody was used to detect protein expression using
EnVision
TM (Dako). Finally, a substrate-chromogen mix was used
for visualization of the immunoreaction. Meyer’s sour hematoxylin
was used as the counterstain. The antibodies used were as follows:
CK7 (clone OV-TL 12/30, 1:100; Dako), CK17 (clone E3, 1:40;
Dako), CK19 (clone RCK108, 1:50; Dako), CK20 (clone KS20.8,
1:50; Dako), ER (clone 1D5, 1:50; Dako), PgR (clone 1A6, 1:50;
Dako), CDX2 (clone CDX 2-88, 1:100; Abcam, Tokyo, Japan),
Orienting Unknown Primary Cancer
PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e31181TTF-1 (clone 8G7G3/1, 1:100; NeoMarkers, Fremont, CA,
USA), WT-1 (clone C-19, 1:500; Santa Cruz Biotechnology,
Inc., Paso Robles, CA, USA), PAX8 (clone 10336-1-AP, 1:200;
Proteintech, Chicago, IL, USA), mammaglobin (clone 304-1A5,
1:200; Dako), GCDFP-15 (clone 23A3, 1:50, Dako), PSA (clone
304-1A5, 50:1; Dako), and uroplakin (clone AU1, 1:50; Abcam).
Immunohistochemical evaluation was performed by three
persons (K. H.,Y. S., and H. T.) blind to clinical information;
.10% positive cancer cells was considered positive at any
intensity. One pathologist (Y. S.) also evaluated whether
identification of the primary tumor site based on the IP was
adequate when referencing hematoxylin-eosin stain results.
Genomic DNA was extracted after microdissection at the
laboratory of SRL (Hamura, Japan) or Pathology and Clinical
Laboratories Divison at the National Cancer Center Hospital. K-
ras gene (accession no. NM_033360.2) mutations at codon 12 or
13 were detected by polymerase chain reaction (PCR) and direct
sequencing (SRL). Deletions of codon 746–750 in exon 19 and
mutations of codon 858 in exon 21 of the EGFR gene (accession
no. NM_005228.3) were detected by high-resolution melting
analysis at our institute [41].
Development of a panel using immunohistochemical
stain results and polymerase chain reaction
We developed an algorithm using the 15 biomarkers to
determine the primary site of the CUPs based on previous
reports (Figure 1) [9,10,13,14,15,16,17,18,19,20,22,24,25,27,28,
40,42,43]. Using the algorithm, primary identified, surgically
resected adenocarcinomas from 12 different sites of 107 samples
were analyzed to calculate sensitivity and specificity of this
algorithm. Tumors which did not match this algorithm except
followings were classified unclassified; tumors with all markers-
negative except for CK19 and ER were classified as breast profile;
tumors did not match this algorithm but CDX2-positive were
classified as digestive profile; and tumors with all markers-negative
except for uroplakin were classified as urothelial profile.
Using the algorithm, all 71 cases of unknown primary
adenocarcinomas were classified into one of the following 9 IPs:
lung profile, gynecological organ profile, i.e. ovarian epithelial
carcinoma, uterine body carcinoma, and cervix carcinoma,
digestive profile, breast profile, prostate profile, urothelial profile,
biliary tract and pancreatic profile, liver/kidney profile, and an
‘‘unclassified’’ profile. Initially, all cases were classified as CK7+/
CK20+, CK7+/CK202, CK72/CK20+, or CK72/CK202,
and subsequently the samples were further analyzed using the
other 13 markers. Patients with digestive profiles were also
examined through K-ras mutations, and patients with lung profiles
were also identified through EGFR mutations. All new data has
been deposited in GenBank (accession no. NM_033360.2 and
accession no. NM_005228.3).
Statistics
The response evaluation was retrospectively performed accord-
ing to the World Health Organization criteria [44] by K.H.
blinded to the IP results. Briefly, a partial response is defined as a
50% reduction in the sum of the tumor cross products. Progressive
disease is defined as a 25% increase in the sum of one or more of
the tumor deposits. Progression-free survival (PFS) was defined as
the time from initiation of chemotherapy until detection of
progression. Deaths of patients who died without evidence of a
recurrence were treated as events. Patients who were lost to follow-
up were treated as censored observations. The overall survival
(OS) period was defined as the time from chemotherapy until the
date of death or the most recent follow-up. Patients who were lost
to follow-up were treated as censored cases. Median PFS and
median survival time (MST) were calculated using the Kaplan-
Meier method, and significance was determined using the log-rank
test. For univariate and multivariate analyses, the Cox propor-
tional regression model was used. All calculations were performed
using SAS version 11.0 (SAS Institute, Inc., Cary, NC, USA).
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